DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer

▴ astrazeneca-olaparib-tablets-treating-ovarian-and-breast-cancer-approved
AstraZeneca's patented olaparib for ovary and breast cancer now in India

Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer.

The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.The tablets are a patented product of the AstraZeneca group, it added.

"The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases," AstraZeneca Pharma India MD Gagan Singh said.

Shares of AstraZeneca Pharma India yeerdayat Rs 1,710.30 per scrip on BSE, up 1.59 per cent from their previous close.

AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India. It is a listed company and is a subsidiary of AstraZeneca Plc, UK. It has a workforce of over 1400 employees across the country that is committed to deliver life-changing medicines to patients through innovative science and global excellence in development and commercialization. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory.


Rated as one of the finest in South East Asia, AstraZeneca’s Indian manufacturing facility has a sophisticated production facility designed to meet the most stringent international standards, conforming to WHO cGMP (current Good Manufacturing Practices) norms. The facility is an ISO 14001 certified company and has a full-fledged environment management system in place.

AstraZeneca India Private Limited (AZIPL) hosts the IT (Global Technology Centre), Global Business Services (Global Commercial Operations) and GMD (Global Medicines Development). AZIPL is governed by a Board of Directors.

Inputs- PTI

Tags : #AstraZeneca #DCGI #OvarianCancer #BreastCancer #AZPL #Karnataka #LatestPharmaNewsAug20 #LatestPharmaUpdateAug20

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Why Are Rare Disease Patients Paying a Fortune When Local Production Could Save Lives?November 07, 2024
Building Lips in the Lab: How Scientists Are Growing Lab Lips to Heal and RebuildNovember 07, 2024
National Cancer Awareness Day: How Small Changes Today Can Save Lives TomorrowNovember 07, 2024
Introducing an AI tool for accurate diagnosis of cholelithiasis on abdominal CT scansNovember 06, 2024
Nat Habit Unveils New Chapter of “Breathe Life Into Your Beauty” Campaign championed by Content Creators and the Launch of VeDHA, digital skin analysis toolNovember 06, 2024
High Level of Pollution Spikes Cardio and Respiratory Problems; Experts Call for Urgent Attention and Action to Mitigate the Risks November 06, 2024
HR leaders ready to shape India's future workforce - XLRI and Leadup Universe seminar in PuneNovember 05, 2024
Nestlé India and SM Sehgal Foundation celebrate 5 years of Project Vriddhi November 05, 2024
Why Tuberculosis Is Still the World’s Leading Killer in 2024 And How We’re Failing to Stop ItNovember 05, 2024
Crompton Launches the Nigella Pro Mixer Grinder to Revolutionize Kitchen ConvenienceNovember 05, 2024
Invisible Shadows: The Growing Crisis of Corneal Blindness in IndiaNovember 05, 2024
Thai AirAsia Entrusts Çelebi India with Ground Handling for New Hyderabad- Bangkok Flights, Signalling Further India Expansion November 05, 2024
Thai AirAsia Entrusts Çelebi India with Ground Handling for New Hyderabad- Bangkok Flights, Signalling Further India Expansion November 05, 2024
Discover 5 Platforms That Turn Your Pennies into PowerhousesNovember 04, 2024
Breathless in the Capital: Post-Diwali Smog Triggers Health Alarms in DelhiNovember 04, 2024
Is Your Diet Fuelling Your Disease? The Shocking Link Between Oil and Multiple SclerosisNovember 04, 2024
Unmasking the Danger Within: The Alarming Rise of Stomach Cancer in IndiaNovember 04, 2024
Hospital-acquired infections are fuelling antimicrobial resistance October 30, 2024
Transforming Patient Care: HealthTech Startups Making Waves in HealthcareOctober 30, 2024
Hospital-acquired infections are fuelling antimicrobial resistance October 30, 2024